Ardelyx receives new patent for Tenapanor
Ardelyx (ARDX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of Isbrela and Xphozah. The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
Disclaimer & DisclosureReport an Issue
- Ardelyx price target raised to $13 from $10 at TD Cowen
- Ardelyx: Commercial Momentum, Expanded Ibsrela Opportunity, and Strengthened IP Underpin Buy Rating
- Ardelyx announces first patient dosed in ACCEL
- 3 Best Stocks to Buy Today, 1/27/2026, According to Top Analysts
- Ardelyx price target raised to $15 from $8 at Jefferies
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.